Who are Capecitabine and Bevacizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capecitabine-and-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Capecitabine and Bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capecitabine and Bevacizumab (Capecitabine and Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoropyrimidine antimetabolite + VEGF inhibitor (monoclonal antibody). Area: Oncology.

phase 2 Fluoropyrimidine antimetabolite + VEGF inhibitor (monoclonal antibody) Thymidylate synthase (capecitabine/5-FU) and VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine and Bevacizumab (Capecitabine and Bevacizumab) — South Eastern European Research Oncology Group. Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Capecitabine and Bevacizumab TARGET	Capecitabine and Bevacizumab	South Eastern European Research Oncology Group	phase 2	Fluoropyrimidine antimetabolite + VEGF inhibitor (monoclonal antibody)	Thymidylate synthase (capecitabine/5-FU) and VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoropyrimidine antimetabolite + VEGF inhibitor (monoclonal antibody) class)

South Eastern European Research Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine and Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-and-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab